Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117(8):2423-2432.
(Source: Blood)
Source: Blood - August 14, 2019 Category: Hematology Tags: Free Research Articles RETRACTIONS Source Type: research
Oxidative hemolysis due to Wilson disease
(Source: Blood)
Source: Blood - August 14, 2019 Category: Hematology Authors: Xu, Z., Berry, B. R. Tags: Free Research Articles, BloodWork, Red Cells, Iron, and Erythropoiesis BLOOD WORK Source Type: research
Never judge a book by its cover: these neutrophils are not reactive!
(Source: Blood)
Source: Blood - August 14, 2019 Category: Hematology Authors: Rieu, J.-B., Vergez, F. Tags: Free Research Articles, BloodWork, Myeloid Neoplasia BLOOD WORK Source Type: research
Acid sphingomyelinase plays a critical role in LPS- and cytokine-induced tissue factor procoagulant activity
Tissue factor (TF) is a cofactor for factor VIIa and the primary cellular initiator of coagulation. Typically, most TF on cell surfaces exists in a cryptic coagulant-inactive state but are transformed to a procoagulant form (decryption) following cell activation. Our recent studies in cell model systems showed that sphingomyelin (SM) in the outer leaflet of the plasma membrane is responsible for maintaining TF in an encrypted state in resting cells, and the hydrolysis of SM leads to decryption of TF. The present study was carried out to investigate the relevance of this novel mechanism in the regulation of TF procoagulant ...
Source: Blood - August 14, 2019 Category: Hematology Authors: Wang, J., Pendurthi, U. R., Rao, L. V. M. Tags: Thrombosis and Hemostasis Source Type: research
Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study
We report a study aimed to provide a "snapshot" of the prevalence of mutations in a real-life CLL cohort still on ibrutinib after at least 3 years of treatment. Of 204 patients who initiated ibrutinib via an early-access program at 29 French Innovative Leukemia Organization (FILO) centers, 63 (31%) were still on ibrutinib after 3 years and 57 provided a fresh blood sample. Thirty patients had a CLL clone ≥0.5 x 109/L, enabling next-generation sequencing (NGS); BTK and PLCG2 mutations were detected in 57% and 13% of the NGS samples, respectively. After median follow-up of 8.5 months from sample collection, the presence o...
Source: Blood - August 14, 2019 Category: Hematology Authors: Quinquenel, A., Fornecker, L.-M., Letestu, R., Ysebaert, L., Fleury, C., Lazarian, G., Dilhuydy, M.-S., Nollet, D., Guieze, R., Feugier, P., Roos-Weil, D., Willems, L., Michallet, A.-S., Delmer, A., Hormigos, K., Levy, V., Cymbalista, F., Baran-Marszak, F Tags: Lymphoid Neoplasia, Brief Reports Source Type: research
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
We report efficacy and long-term follow-up of 21 patients with relapsed/refractory (R/R) FL (n = 8) and tFL (n = 13) treated on a phase 1/2 clinical trial with cyclophosphamide and fludarabine lymphodepletion followed by infusion of 2 x 106 CD19-directed chimeric antigen receptor–modified T (CAR-T) cells per kilogram. The complete remission (CR) rates by the Lugano criteria were 88% and 46% for patients with FL and tFL, respectively. All patients with FL who achieved CR remained in remission at a median follow-up of 24 months. The median duration of response for patients with tFL was 10.2 months at a median follow-up...
Source: Blood - August 14, 2019 Category: Hematology Authors: Hirayama, A. V., Gauthier, J., Hay, K. A., Voutsinas, J. M., Wu, Q., Pender, B. S., Hawkins, R. M., Vakil, A., Steinmetz, R. N., Riddell, S. R., Maloney, D. G., Turtle, C. J. Tags: Immunobiology and Immunotherapy, Lymphoid Neoplasia, Brief Reports, Clinical Trials and Observations Source Type: research
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
High-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) is the standard of care for relapsed or primary refractory (rel/ref) chemorefractory diffuse large B-cell lymphoma. Only 50% of patients are cured with this approach. We investigated safety and efficacy of CD19-specific chimeric antigen receptor (CAR) T cells administered following HDT-ASCT. Eligibility for this study includes poor-risk rel/ref aggressive B-cell non-Hodgkin lymphoma chemosensitive to salvage therapy with: (1) positron emission tomography–positive disease or (2) bone marrow involvement. Patients underwe...
Source: Blood - August 14, 2019 Category: Hematology Authors: Sauter, C. S., Senechal, B., Riviere, I., Ni, A., Bernal, Y., Wang, X., Purdon, T., Hall, M., Singh, A. N., Szenes, V. Z., Yoo, S., Dogan, A., Wang, Y., Moskowitz, C. H., Giralt, S., Matasar, M. J., Perales, M.-A., Curran, K. J., Park, J., Sadelain, M., B Tags: Immunobiology and Immunotherapy, Transplantation, Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research
PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia-initiating cells
Oncogenic mutations confer on cells the ability to propagate indefinitely, but whether oncogenes alter the cell fate of these cells is unknown. Here, we show that the transcriptional regulator PRDM16s causes oncogenic fate conversion by transforming cells fated to form platelets and erythrocytes into myeloid leukemia stem cells (LSCs). Prdm16s expression in megakaryocyte-erythroid progenitors (MEPs), which normally lack the potential to generate granulomonocytic cells, caused AML by converting MEPs into LSCs. Prdm16s blocked megakaryocytic/erythroid potential by interacting with super enhancers and activating myeloid maste...
Source: Blood - August 14, 2019 Category: Hematology Authors: Hu, T., Morita, K., Hill, M. C., Jiang, Y., Kitano, A., Saito, Y., Wang, F., Mao, X., Hoegenauer, K. A., Morishita, K., Martin, J. F., Futreal, P. A., Takahashi, K., Nakada, D. Tags: Hematopoiesis and Stem Cells, Myeloid Neoplasia Source Type: research
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
In conclusion, brentuximab-AVD without bleomycin or radiation produced a high complete response rate, with most patients requiring only 4 total cycles of therapy. Because toxicity was higher than would be expected from AVD alone, this method may not be appropriate for early-stage patients with a highly favorable prognosis. This trial was registered at www.clinicaltrials.gov as #NCT01534078. (Source: Blood)
Source: Blood - August 14, 2019 Category: Hematology Authors: Abramson, J. S., Arnason, J. E., LaCasce, A. S., Redd, R., Barnes, J. A., Sokol, L., Joyce, R., Avigan, D., Neuberg, D., Takvorian, R. W., Hochberg, E. P., Bello, C. M. Tags: Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research
The simpler, the better: oral arsenic for acute promyelocytic leukemia
Arsenic trioxide and all-trans retinoic acid have become the frontline treatments for patients with acute promyelocytic leukemia (APL). Despite the long wait for an oral arsenic drug, a commercially available agent, realgar–indigo naturalis formula (RIF), was not launched in China until 2009. Since then, over 5000 APL patients have been treated with oral RIF in China. Oral arsenic not only shows a clinical efficacy comparable to that of IV formulations but also displays a better safety profile, improved quality of life, and lower medical costs for patients. The promising results promote incorporating an outpatient po...
Source: Blood - August 14, 2019 Category: Hematology Authors: Zhu, H.-H., Hu, J., Lo-Coco, F., Jin, J. Tags: Free Research Articles, Myeloid Neoplasia, CME article, Review Articles, Clinical Trials and Observations Source Type: research
An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma
Although a pathogenic role for the Epstein-Barr virus (EBV) is largely undisputed for tumors that are consistently EBV genome positive (eg, nasopharyngeal carcinoma, endemic Burkitt lymphoma), this is not the case for classical Hodgkin lymphoma (cHL), a tumor with only a variable EBV association. In light of recent developments in immunotherapeutics and small molecules targeting EBV, we believe it is now timely to reevaluate the role of EBV in cHL pathogenesis. (Source: Blood)
Source: Blood - August 14, 2019 Category: Hematology Authors: Murray, P. G., Young, L. S. Tags: Immunobiology and Immunotherapy, Lymphoid Neoplasia, Blood Spotlight Source Type: research
Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD
Painful vaso-occlusive crisis (VOC) is the most common complication of sickle cell disease (SCD). Increasing evidence suggests that vaso-occlusion is initiated by increased adherence of sickle red blood cells (RBCs) to the vascular endothelium. Thus, the mechanisms that remove endothelial-attached sickle RBCs from the microvasculature are expected to be critical for optimal blood flow and prevention of VOC in SCD. We hypothesized that patrolling monocytes (PMos), which protect against vascular damage by scavenging cellular debris, could remove endothelial-adherent sickle RBCs and ameliorate VOC in SCD. We detected RBC (GPA...
Source: Blood - August 14, 2019 Category: Hematology Authors: Liu, Y., Zhong, H., Bao, W., Mendelson, A., An, X., Shi, P., Chou, S. T., Manwani, D., Yazdanbakhsh, K. Tags: Sickle Cell Disease, Transfusion Medicine, Plenary Papers, Red Cells, Iron, and Erythropoiesis Source Type: research
The case for CAR T-cell therapy in follicular lymphomas
(Source: Blood)
Source: Blood - August 14, 2019 Category: Hematology Authors: Bishop, M. R. Tags: Free Research Articles COMMENTS Source Type: research
Too big for flow
(Source: Blood)
Source: Blood - August 7, 2019 Category: Hematology Authors: Almire, C., Chapuis, N. Tags: Free Research Articles, BloodWork, Lymphoid Neoplasia BLOOD WORK Source Type: research
In vitro evaluation of factor IX as novel treatment for factor XI deficiency
(Source: Blood)
Source: Blood - August 7, 2019 Category: Hematology Authors: Bakhtiari, K., Meijers, J. C. M. Tags: Thrombosis and Hemostasis Letter to Blood Source Type: research
